Andrew J. Hirsch
Net Worth

Last updated:

What is Andrew J. Hirsch net worth?

The estimated net worth of Mr. Andrew J. Hirsch is at least $1,851,280 as of 7 Nov 2024. He owns shares worth $27,400 as insider and has received compensation worth at least $1,823,880 in C4 Therapeutics, Inc..

What is the salary of Andrew J. Hirsch?

Mr. Andrew J. Hirsch salary is $607,960 per year as Chief Executive Officer, Pres & Director in C4 Therapeutics, Inc..

How old is Andrew J. Hirsch?

Mr. Andrew J. Hirsch is 54 years old, born in 1971.

What stocks does Andrew J. Hirsch currently own?

As insider, Mr. Andrew J. Hirsch owns shares in one company:

Company Title Shares Price per share Total value
C4 Therapeutics, Inc. (CCCC) Chief Executive Officer, Pres & Director 10,000 $2.74 $27,400

What does C4 Therapeutics, Inc. do?

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

CCCC logo
CCCC
C4 Therapeutics, Inc.
$2.74

Andrew J. Hirsch insider trading

C4 Therapeutics, Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 12,500 N/A N/A
Option
Performance Restricted Stock Units 12,500 N/A N/A
Option
Common Stock 7,500 N/A N/A
Option
Performance Restricted Stock Units 7,500 N/A N/A
Option
Common Stock 7,500 N/A N/A
Option
Performance Restricted Stock Units 7,500 N/A N/A
Option
Common Stock 12,500 N/A N/A
Option
Performance Restricted Stock Units 12,500 N/A N/A
Option
Common Stock 12,500 N/A N/A
Option
Performance Restricted Stock Units 12,500 N/A N/A
Purchase
Common Stock 10,000 $8.4 $84,000

C4 Therapeutics key executives

C4 Therapeutics, Inc. executives and other stock owners filed with the SEC: